Perspective Therapeutics raises $87.4M in private placement and acquires cGMP manufacturing facility

Perspective Therapeutics, Inc.

Gross proceeds of $87.4M from sale of 92,009,981 shares at $0.95/share; Lantheus to purchase $57.4M.
Acquired 11,500 sq ft cGMP-compliant facility in Somerset, NJ from Lantheus for Pb-labeled radiopharmaceuticals.
Net proceeds to fund R&D, clinical trials, manufacturing, and general corporate purposes.
Registration rights agreement filed to register resale of shares with SEC.
Facility acquisition is part of a strategic collaboration with Lantheus announced Jan 9, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Placement Agency Agreement with Oppenheimer & Co. Inc. valued at 5.85% of the gross proceeds (effective 2024-03-04).

Action: entry
Agreement: underwriting
Counterparty: Oppenheimer & Co. Inc.
Value: 5.85% of the gross proceeds
Effective: 2024-03-04

Exact text from the filing

The Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the “Placement Agency Agreement”), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the “Placement Agents”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Perspective Therapeutics, Inc. entered into Investment Agreement with certain accredited institutional investors valued at approximately $87.4 million (effective 2024-03-04).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited institutional investors
Value: approximately $87.4 million
Effective: 2024-03-04

Exact text from the filing

On March 4, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain accredited institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), 92,009,981 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $0.95 per share, representing the closing price of the Common Stock on March 1, 2024.

View on SEC.gov

739 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-006845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.